Alpha Thalassemia Causes Hydrops Fetalis
Alpha-thalassemia, specifically homozygous alpha-thalassemia (also known as Hemoglobin Bart's hydrops fetalis syndrome), is the type of thalassemia that causes hydrops fetalis. This occurs when a fetus inherits deletions of all four alpha-globin genes (genotype ζ--/ζ--), resulting in the complete absence of functional alpha-globin chains 1.
Pathophysiology and Clinical Presentation
The mechanism of hydrops development is severe intrauterine hypoxia from early gestational age due to the formation of nonfunctional hemoglobin. When alpha-globin genes are absent, fetal gamma-globin chains form tetramers (γ4) called Hemoglobin Bart's, which is an ineffective oxygen carrier and cannot adequately deliver oxygen to fetal tissues 1. Small amounts of Hemoglobin Portland (ζ2γ2) may form if embryonic zeta-globin genes remain intact, allowing some fetuses to survive into the second or third trimester 2.
Hydrops fetalis from alpha-thalassemia typically presents in the late second or early third trimester, though it can occasionally be detected as early as 12-14 weeks of gestation 1, 3. The diagnosis can be confirmed by detecting common DNA deletions or point mutations, or by identifying abnormal Bart's hemoglobin in fetal blood samples 1.
Epidemiology and Clinical Significance
Alpha-thalassemia is the most common hemoglobinopathy causing nonimmune hydrops fetalis (NIHF), particularly in Southeast Asian populations where it accounts for 28-55% of NIHF cases 1. In most other populations, it accounts for approximately 10% of NIHF cases 1. This condition is increasingly important in the United States due to immigration patterns from high-prevalence regions 4.
Parents can be screened by evaluating mean corpuscular volume (MCV), which will be <80 fL in thalassemia carriers 1. When both parents are carriers of the Southeast Asian deletion type (-/αα), there is a 25% risk with each pregnancy of producing a fetus with homozygous alpha-thalassemia 2, 5.
Clinical Outcomes and Management Considerations
Without treatment, all affected fetuses die in utero or shortly after birth 2. However, with advances in intrauterine transfusion and intensive perinatal care, a small number of survivors now exist, though they face significant long-term complications including chronic anemia, ongoing hemolysis, and iron overload from intensive transfusion requirements 6, 2.
The condition also causes significant maternal morbidity, including risks of pre-eclampsia, thyrotoxic cardiomyopathy from hyperplacentosis, and complications from delivering a hydropic fetus 7, 4.
Key Distinction from Beta-Thalassemia
Beta-thalassemia does not cause hydrops fetalis because fetal hemoglobin (HbF, α2γ2) production remains intact during fetal life, as beta-globin chains are not required for fetal hemoglobin synthesis. Beta-thalassemia only manifests clinically after birth when the switch from gamma-globin to beta-globin production occurs 1.